Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

OSI Pharmaceuticals Trims 2010 Revenue Outlook

By Pharmaceutical Processing | December 22, 2009

MELVILLE, N.Y. (AP) — OSI Pharmaceuticals Inc. on Tuesday trimmed its 2010 revenue outlook citing a potential regulatory roadblock to the cancer drug Tarceva. However, the drug developer still expects growth of 10 percent or more in adjusted earnings per share. The company now expects 2010 revenue to grow by a percentage in the mid-teens. On Dec. 3, the company laid out an outlook for revenue growth in the high teens over the next several years, while reaffirming 2009 revenue guidance of about $425 million. Analysts polled by Thomson Reuters expect 2009 revenue of about $418.8 million and 2010 revenue of about $476.3 million. The outlook reduction comes a week after a Food and Drug Administration advisory panel recommended against expanding approval of the company’s lung cancer drug Tarceva to patients who are already responding to chemotherapy. The drug is already approved as a treatment for patients whose cancer has spread despite chemotherapy treatment. The FDA is not required to follow the advice of its panels, though it usually does. A decision on Tarceva is expected by Jan. 18. Tarceva is also sold as a treatment for pancreatic cancer and in partnership with Roche’s Genentech unit.

Related Articles Read More >

These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
Thermo Fisher Scientific
Thermo Fisher to invest $2B on U.S. manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE